Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E; SPARTACUSS Group. Patrikidou A, et al. Among authors: heng d. Clin Genitourin Cancer. 2024 Oct 5;22(6):102230. doi: 10.1016/j.clgc.2024.102230. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39461026 Free article.
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E; Spartacuss Group. Fotia G, et al. Among authors: heng d. Clin Genitourin Cancer. 2024 Oct;22(5):102185. doi: 10.1016/j.clgc.2024.102185. Epub 2024 Aug 9. Clin Genitourin Cancer. 2024. PMID: 39217072 Free article.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
Barragan-Carrillo R, Saad E, Saliby RM, Sun M, Albiges L, Bex A, Heng D, Mejean A, Motzer RJ, Plimack ER, Powles T, Rini BI, Zhang T, Choueiri TK. Barragan-Carrillo R, et al. Among authors: heng d. Eur Urol. 2024 Nov 5:S0302-2838(24)02681-2. doi: 10.1016/j.eururo.2024.10.019. Online ahead of print. Eur Urol. 2024. PMID: 39505582 Review.
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.
Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallée LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO, Alimohamed N, Huynh M, Kassouf W, Noonan K, Power N. Graham J, et al. Among authors: heng dyc. Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041. Can Urol Assoc J. 2024. PMID: 39500366 Free PMC article. No abstract available.
An Assessment of an Inpatient Robotic Nurse Assistant: A Mixed-Method Study.
Lim YW, Tan SW, Tan CYB, Lee DHM, Siow WT, Heng DGN, Mukhopadhyay A, Lim JC, Sivadas S, Teo ELK, Ho LKY, Phua J. Lim YW, et al. Among authors: heng dgn. J Med Syst. 2024 Oct 22;48(1):99. doi: 10.1007/s10916-024-02117-4. J Med Syst. 2024. PMID: 39436455 Free PMC article.
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Choueiri TK, et al. Among authors: heng dyc. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. Lancet. 2024. PMID: 39284329 Clinical Trial.
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. Barata P, et al. Among authors: heng dyc. J Clin Oncol. 2024 Nov 20;42(33):3911-3916. doi: 10.1200/JCO.24.00767. Epub 2024 Sep 10. J Clin Oncol. 2024. PMID: 39255440 Free PMC article. Clinical Trial.
485 results